GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » Liabilities-to-Assets

Greenwich LifeSciences (Greenwich LifeSciences) Liabilities-to-Assets : 0.07 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Greenwich LifeSciences's Total Liabilities for the quarter that ended in Mar. 2024 was $0.39 Mil. Greenwich LifeSciences's Total Assets for the quarter that ended in Mar. 2024 was $5.51 Mil. Therefore, Greenwich LifeSciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.07.


Greenwich LifeSciences Liabilities-to-Assets Historical Data

The historical data trend for Greenwich LifeSciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenwich LifeSciences Liabilities-to-Assets Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial 51.00 0.04 0.01 0.02 0.04

Greenwich LifeSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.03 0.04 0.07

Competitive Comparison of Greenwich LifeSciences's Liabilities-to-Assets

For the Biotechnology subindustry, Greenwich LifeSciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenwich LifeSciences's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's Liabilities-to-Assets falls into.



Greenwich LifeSciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Greenwich LifeSciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=0.294/6.995
=0.04

Greenwich LifeSciences's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=0.39/5.51
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Greenwich LifeSciences  (NAS:GLSI) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Greenwich LifeSciences Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Greenwich LifeSciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenwich LifeSciences (Greenwich LifeSciences) Business Description

Traded in Other Exchanges
N/A
Address
3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Executives
Snehal Patel director, officer: CHIEF EXECUTIVE OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson officer: VPC AND REGULATORY AFFAIRS 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty director, officer: CHIEF MEDICAL OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams director 2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel 10 percent owner 3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel 10 percent owner 50726 LAKESIDE DRIVE, GRANGER IN 46530

Greenwich LifeSciences (Greenwich LifeSciences) Headlines